Effects of night-time use of rotigotine on nocturnal symptoms in Parkinson's disease

Parkinson's Disease

Volumn 2015, Issue , 2015, Pages

  Vallderiola, Francesc ^a,b   Compta, Yaroslau ^a,b   Aparicio, Javier ^c   Tarradellas, Jaume ^d   Salazar, Gabriel ^e   Oliver, Josep María ^f   Callén, Antonio ^g   Delgado, Tania ^h   Nobbe, Fritz ⁱ  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d Clinica Dexeus Barcelona   (Spain)

^e HOSPITAL DE TERRASSA   (Spain)

^f Hospital de Reus   (Spain)

^g PARC SANITARI SANT JOAN DE DÉU   (Spain)

^h HOSPITAL DE SABADELL   (Spain)

ⁱ Juaneda Clinic   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; ROTIGOTINE;

AGED; AKINESIA; ANXIETY; ARM PAIN; ARTICLE; BLURRED VISION; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FLATULENCE; GASTROINTESTINAL DISEASE; HALLUCINATION; HUMAN; HYPOTENSION; LEG PAIN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE ASSESSMENT; NOCTURIA; OPEN STUDY; PAIN; PARKINSON DISEASE; PARKINSON DISEASE QUESTIONNAIRE 8; PARKINSON DISEASE SLEEP SCALE 2; PATIENT DECISION MAKING; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RASH; RESTLESS LEGS SYNDROME; RESTLESSNESS; SCORING SYSTEM; SLEEP DISORDER; SLEEP DISORDER ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VERTIGO; VISUAL ANALOG SCALE; VISUAL DISORDER; VIVID DREAM;

EID: 84947222226     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1155/2015/475630     Document Type: Article

References (21)

1. E. B. Forsaa, J. P. Larsen, T. Wentzel-Larsen, K. Herlofson, and G. Alves, "Predictors and course of health-related quality of life in Parkinson's disease," Movement Disorders, vol. 23, no. 10, pp. 1420-1427, 2008.
2. A. Videnovic and D. Golombek, "Circadian and sleep disorders in Parkinson's disease," Experimental Neurology, vol. 243, pp. 45-56, 2013.
3. T. J. Swick, J. H. Friedman, K. R. Chaudhuri et al., "Associations between severity of motor function and nonmotor symptoms in Parkinson's disease: a post hoc analysis of the RECOVER study," European Neurology, vol. 71, no. 3-4, pp. 140-147, 2014.
4. K. R. Chaudhuri, "The dopaminergic basis of sleep dysfunction and non motor symptoms of Parkinson's disease: evidence from functional imaging," Experimental Neurology, vol. 216, no. 2, pp. 247-248, 2009.
5. N. Giladi, A. Fichtner, W. Poewe, and B. Boroojerdi, "Rotig-otine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson's disease," Journal of Neural Transmission, vol. 117, no. 12, pp. 1395-1399, 2010.
6. C. Trenkwalder, B. Kies, M. Rudzinska et al., "Rotigotine efects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER)," Movement Disorders, vol. 26, no. 1, pp. 90-99, 2011.
7. F. Stocchi, P. Jenner, and J. A. Obeso, "When do levodopa motor fuctuations frst appear in Parkinson's disease?" European Neurology, vol. 63, no. 5, pp. 257-266, 2010.
8. P. Barone, M. Amboni, C. Vitale, and V. Bonavita, "Treatment of nocturnal disturbances and excessive daytime sleepiness in Parkinson's disease," Neurology, vol. 63, no. 8, pp. S35-S38, 2004.
9. M. Canesi, C. B. Mariani, I. U. Isaias, and G. Pezzoli, "Nighttime use of rotigotine in advanced Parkinson's disease," Functional Neurology, vol. 25, no. 4, pp. 201-204, 2010.
10. J.-P. Elshof, M. Braun, J.-O. Andreas, M. Middle, and W. Cawello, "Steady-state plasma concentration profle of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies," Clinical Terapeutics, vol. 34, no. 4, pp. 966-978, 2012.
11. European Medicines Agency, Neupro (Rotigotine): European Public Assessment Report-Summary of Product Characteristics, European Medicines Agency, 2014, http://www.ema.europa.eu/docs/en GB/document library/EPAR-Product Information/human/000626/WC500026397.pdf.
12. K. Ray Chaudhuri, P. Martinez-Martin, A. Antonini et al., "Rotigotine and specifc non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER," Parkinsonism and Related Disorders, vol. 19, no. 7, pp. 660-665, 2013.
13. A. J. Hughes, S. E. Daniel, L. Kilford, and A. J. Lees, "Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases," Journal of Neurology Neuro-surgery and Psychiatry, vol. 55, no. 3, pp. 181-184, 1992.
14. C. Trenkwalder, R. Kohnen, B. Högl et al., "Parkinson's disease sleep scale-validation of the revised version PDSS-2," Movement Disorders, vol. 26, no. 4, pp. 644-652, 2011.
15. V. Peto, C. Jenkinson, and R. Fitzpatrick, "PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures," Journal of Neurology, vol. 245, supplement 1, pp. S10-S14, 1998.
16. A. Antonini, L. Bernardi, D. Calandrella, F. Mancini, and M. Plebani, "Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders," Functional Neurology, vol. 25, no. 1, pp. 21-25, 2010.
17. K. R. Chaudhuri, S. Pal, and C. Brefel-Courbon, "'Sleep attacks' or 'unintended sleep episodes' occur with dopamine agonists: is this a class efect?" Drug Safety, vol. 25, no. 7, pp. 473-483, 2002.
18. P. E. O'Suilleabhain and R. B. Dewey Jr., "Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease," Archives of Neurology, vol. 59, no. 6, pp. 986-989, 2002.
19. S. Fenu, J. Wardas, and M. Morelli, "Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease," Behavioural Pharmacology, vol. 20, no. 5-6, pp. 363-379, 2009.
20. V. Voon, M. Sohr, A. E. Lang et al., "Impulse control disorders in parkinson disease: a multicenter case-control study," Annals of Neurology, vol. 69, no. 6, pp. 986-996, 2011.
21. C. Trenkwalder, B. Kies, P. Dioszeghy et al., "Rotigotine transdermal system for the management of motor function and sleep disturbances in Parkinson's disease: results from a 1-year, open-label extension of the RECOVER study," Basal Ganglia, vol. 2, no. 2, pp. 79-85, 2012.